向秋萍博士主要从事创新药物研发工作，在人工智能药物筛选、药物模拟、成药性先导化合物发现等领域积累了丰富的经验。近年来针对前列腺癌及白血病耐药等重大临床需求，申请人基于表观遗传学溴结构域靶标（CBP、BRD4、TRIM24）进行合理药物设计，已获得几类成药性小分子。目前已在SCI期刊发表论文18篇，以第一作者或通讯作者发表SCI论文7篇，申请专利5项（授权两项）。作为项目负责人承担国家自然科学青年基金，中国博士后面上项目以及省市基金等5项。

 

2009/9-2013/6   本科，湖南师范大学

2013/9-2016/6   硕士，中国科学院广州生物医药与健康研究院

2016/9-2019/6   博士，中国科学院广州生物医药与健康研究院

 

2019/7-2021/6   博士后，中国科学院广州生物医药与健康研究院 

2019/10-2020/8  博士后，威斯康星大学麦迪逊分校

2021/7-2022/3   助理研究员/副研究员，中国科学院广州生物医药与健康研究院

2022/4-至今     副研究员，国科宁波生命与健康产业研究院

 

2019年，广东省自然科学奖二等奖（排名第七）

 

国家自然科学青年基金，2021.01-2023.12，主持。

中国博士后科学基金面上项目，2019.07-2021.06，主持，已结题。

宁波市自然科学基金，2022.09-2025.08，主持。

 

第一作者或通讯作者论文

[1] Qiuping Xiang^# Chao Wang,^# Tianbang Wu,^# Cheng Zhang, Qingqing Hu, Guolong Luo, Jiankang Hu, Xiaoxi Zhuang, Lingjiao Zou, Hui Shen, Xishan Wu, Yan Zhang, Xiangqian Kong, Jinsong Liu, and Yong Xu^*. Design, Synthesis, and Biological Evaluation of 1-(Indolizin-3-yl)ethan-1-ones as CBP Bromodomain Inhibitors for the Treatment of Prostate Cancer. Journal of Medicinal Chemistry, 2022, 65, 785–810.

[2] Hongrui Xu, Guolong Luo, Tianbang Wu, Jiankang Hu, Chao Wang, Xishan Wu, Yan Zhang*, Yong Xu,*, and Qiuping Xiang*. Structural insights revealed by the cocrystal structure of CCS1477 in complex with CBP bromodomain. Biochemical and Biophysical Research Communications, 2022,623,17-22.

[3] Qiuping Xiang#,* Guolong Luo# Cheng Zhang, Qingqing Hu, Chao Wang, Tianbang Wu, Hongrui Xu, Jiankang Hu, Xiaoxi Zhuang, Maofeng Zhang, Shuang Wu, Jinxin Xu, Yan Zhang, Jinsong Liu, and Yong Xu*. Discovery, optimization and evaluation of 1-(indolin-1-yl)ethan-1-ones as novel selective TRIM24/BRPF1 bromodomain inhibitors. European Journal of Medicinal Chemistry, 2022,236,114311.

[4] Qiuping Xiang^#, Chao Wang^#, Yan Zhang, Xiaoqian Xue, Ming Song, Cheng Zhang, Chenchang Li, Chun Wu, Kuai Li, Xiaoyan Hui, Yulai Zhou, Jeff B. Smaill, Adam V. Patterson, Donghai Wu, Ke Ding, Yong Xu^*. Discovery and optimization of 1-(1H-indol-1-yl)ethanone derivatives as CBP/EP300 bromodomain inhibitors for the treatment of castration resistant prostate cancer. European Journal of Medicinal Chemistry, 2018, 147, 238?252.

[5] Qiuping Xiang^#, Yan Zhang^#, Jiaguo Li^#, Xiaoqian Xue, Chao Wang, Ming Song, Cheng Zhang, Rui Wang, Chenchang Li, Chun Wu, Yulai Zhou, Xiaohong Yang, Guohui Li, Ke Ding, and Yong Xu^*. Y08060: a selective BET inhibitor for treatment of prostate cancer. ACS Medicinal Chemistry Letters, 2018, 9, 262?267.

[6] Lingjiao Zou^#, Qiuping Xiang^#, Xiaoqian Xue^#, Cheng Zhang, Chenchang Li, Chao Wang, Qiu Li, Rui Wang, Shuang Wu, Yulai Zhou, Yan Zhang, and Yong Xu^*. Y08197, a novel and selective CBP and EP300 bromodomain inhibitor for treatment of prostate cancer. Acta Pharmacologica Sinica, 2019, 40, 1436?1447.

[7] Tianbang Wu^#, Qiuping Xiang^#, Chao Wang^#, Chun Wu, Cheng Zhang, Maofeng Zhang, Zhaoxuan Liu, Yan Zhang^*, Lin-jiu Xiao^*, and Yong Xu^*. Y06014 is a selective BET inhibitor for the treatment of prostate cancer. Acta Pharmacologica Sinica, 2021, 42, 2120?2131.